FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease

This entry was posted by admin on March 23, 2023 at 11:56 am

FDA advisors voted against the effectiveness of Biogen’s investigational ALS drug, which could become the first to target a genetic cause of the disease.